Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered With Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects With Select Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1 Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered With Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects With Select Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lirilumab (Primary) ; Ipilimumab
  • Indications Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 11 Oct 2016 Results of this trial and other (CA223-001; NCT01714739) trial presented at the 41st European Society for Medical Oncology Congress
    • 09 Oct 2016 Results published in the Bristol-Myers Squibb Media Release
    • 09 Oct 2016 According to a Bristol-Myers Squibb media release, safety data from CA223-001 and CA223-002 trials presented at ESMO 2016 Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top